Mirati Therapeutics Inc
Suletud
SektorTervishoid
0
Ülevaade
Aktsiahinna muutus
24h
Min
Max
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | -0.05% downside |
Uudiste sentiment
By Acuity
50%
50%
171 / 346 Pingereas Healthcare
Mirati Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Mirati Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
-0.05% langus
12 kuu keskmine prognoos
Keskmine 58.67 USD -0.05%
Kõrge 59 USD
Madal 58 USD
Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
171 / 346 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
EBITDA
Ärikasum
$
Ettevõttest Mirati Therapeutics Inc
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
